As seen on shelf at Walgreens, having a major pharma player like Bayer HealthCare field what essentially is a hangover-relief product adds credibility, not to mention a little more shelf presence, to similar products like Living Essentials’ Chaser Plus.
XenaCare receives ‘Best New Product’ award at conference
DELRAY BEACH, Fla. XenaCare Holdings on Monday announced that its stage 2 pain reliever, Cobroxin, has won the award for “Best New Product,” sponsored by Drug Store News, at the recent ECRM Health held in Miami.
“It is an honor to have Cobroxin chosen as the best new product at ECRM,” stated Frank Rizzo, president of XenaCare. “This award … supports our belief that Cobroxin will soon become the preferred alternative to current opiate and acetaminophen-based analgesics,” he concluded.
Retailer attendees nominate and vote on “Best New Product” at the show.
Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain. Recently, XenaCare Holdings was awarded the exclusive license for marketing and distributing Cobroxin within the United States.
As part of Drug Store News’ sponsorship of the award, XenaCare Holdings will receive a full-page advertisement in an upcoming issue of Drug Store News.
New research finds antidepressant may ease symptoms of IBS
BEIJING A research article published Aug. 7 in the World Journal of Gastroenterology measured the efficacy of the prescription antidepressant imipramine in the treatment of symptoms of irritable bowel syndrome. Patients diagnosed with IBS who failed treatment with conventional therapy were enrolled to receive a 12-week course of low-dose imipramine.
The results were significant for showing improvement in global symptoms during and after 12 weeks of therapy with the medication. There also was notable improvement in general quality of life as measured by a standardized questionnaire, researchers reported.
The authors believe that imipramine is a potentially effective treatment for IBS symptoms in patients for whom conventional therapy has failed. This trial was designed and implemented at the American University of Beirut Medical Center, Beirut, Lebanon between December 2004 and May 2006. Research funding was provided by a private research fund from the Division of Gastroenterology of the American University of Beirut Medical Center. The preliminary abstract of the trial was selected for oral presentation at the American College of Gastroenterology 71st Annual Scientific Meeting (October 20, 2006, Las Vegas, Nev., USA) and was awarded the American College of Gastroenterology /Novartis Motility Abstract Award.